Back to top Open menu arrow
Download PDF Reprints

The Journal of
Clinical Psychiatry
Members only

Original Research Early Career Psychiatrists February 11, 2026

Postmarketing Safety of Transcranial Magnetic Stimulation: A 10-Year MAUDE Database Analysis of Adverse Events and Technological Advancements

; ; ; ;

J Clin Psychiatry 2026;87(2):25m16155

Abstract

Background: Transcranial magnetic stimulation (TMS) is an FDA-cleared neuromodulation technique with expanding clinical applications beyond major depressive disorder. Despite increasing utilization, there has been no published, device-agnostic analysis of TMS-related adverse events (AEs) using the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database.

Objective: To characterize the real-world safety profile of TMS devices based on MAUDE-reported AEs, including symptom patterns, manufacturer-level variations, device issues, and reporting delays, while contextualizing findings through a review of technological advancements in TMS.

Methods: All reports under device code OBP were extracted from MAUDE through April 2025. After deduplication, 200 unique reports were analyzed descriptively. A focused literature review was also conducted to trace safety and innovation trends in TMS device development.

Results: Of 200 reports, 94.7% involved injury, 4.1% malfunction, and 1.2% death. Common symptoms included anxiety (8.2%), neurocognitive changes (8.0%), seizures (6.9%), headache (6.9%), and tinnitus (5.6%). Neuronetics accounted for 45.5% of reports, likely reflecting market share. Median reporting delay was 1.4 months, with some exceeding 6 years. The literature review identified major innovations, including figure-of-eight and H-coils, double-containment coils, seizure risk screening, and advanced circuitry (eg, insulated-gate bipolar transistors and metal-oxide-semiconductor field-effect transistors) enabling magnetic resonance imaging–guided and accelerated protocols. Exploratory developments include wearable systems, auricular stimulation, and artificial intelligence–based individualization.

Conclusion: MAUDE data provide novel insights into TMS safety in real-world settings. Although serious AEs are rare, standardized reporting and continued device innovation are essential to ensure safe and effective clinical use.

J Clin Psychiatry 2026;87(2):25m16155

Author affiliations are listed at the end of this article.

Members Only Content

This full article is available exclusively to Professional tier members. Subscribe now to unlock the HTML version and gain unlimited access to our entire library plus all PDFs. If you're already a subscriber, please log in below to continue reading.

Subscribe Now

Already a member? Log in

  1. Janicak PG, Dokucu ME. Transcranial magnetic stimulation for the treatment of major depression. Neuropsychiatr Dis Treat. 2015;11:1549–1560. PubMed CrossRef
  2. Lefaucheur JP, Aleman A, Baeken C, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): an update (2014–2018). Clin Neurophysiol Off J Int Fed Clin Neurophysiol. 2020;131(2):474–528. PubMed CrossRef
  3. Rossi S, Antal A, Bestmann S, et al. Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: expert guidelines. Clin Neurophysiol. 2021;132(1):269–306. PubMed CrossRef
  4. Lipton RB, Dodick DW, Silberstein SD, et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol. 2010;9(4):373–380. PubMed CrossRef
  5. Young JR, Galla JT, Appelbaum LG. Transcranial magnetic stimulation treatment for smoking cessation: an introduction for primary care clinicians. Am J Med. 2021;134(11):1339–1343. PubMed CrossRef
  6. Cohen SL, Bikson M, Badran BW, et al. A visual and narrative timeline of US FDA milestones for transcranial magnetic stimulation (TMS) devices. Brain Stimul Basic Transl Clin Res Neuromodulation. 2022;15(1):73–75. PubMed CrossRef
  7. US Food and Drug Administration. FDA permits marketing of transcranial magnetic stimulation for treatment of obsessive compulsive disorder. August 17, 2018. https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-transcranial-magnetic-stimulation-treatment-obsessive-compulsive-disorder
  8. Wexler A, Nagappan A, Kopyto D, et al. Off-label promotion of transcranial magnetic stimulation on provider websites. Brain Stimul. 2021;14(3):723–724. PubMed CrossRef
  9. Product Classification. Transcranial Magnetic Stimulator. Accessed November 27, 2025. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/cfm?ID=OBP
  10. Tendler A, Gersner R, Roth Y, et al. Deep TMS: a comprehensive summary of adverse events from five multicenter trials. Brain Stimul Basic Transl Clin Res neuromodulation. 2023;16(4):1123–1125. PubMed CrossRef
  11. Thynne TR, Gabb GM. Editorial: limitations of randomised controlled trials as evidence of drug safety. Aust Prescr. 2023;46(2):22–23. PubMed CrossRef
  12. Manufacturer and User Facility Device Experience (MAUDE) Database. Accessed May 22, 2025. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/cfm
  13. Microsoft Excel. Microsoft Corporation; 2024. https://www.microsoft.com/en-us/microsoft-365/excel
  14. Terminologies for Categorized Adverse Event Reporting (AER): terms, terminology and codes. International Medical Device Regulators Forum. March 3, 2025. Accessed May 20, 2025. https://www.imdrf.org/documents/terminologies-categorized-adverse-event-reporting-aer-terms-terminology-and-codes
  15. 21 CFR Part 803—Medical Device Reporting. Accessed Nov 25, 2025. https://ecfr.gov/current/title-21/part-803
  16. Sachdev PS, Blacker D, Blazer DG, et al. Classifying neurocognitive disorders: the DSM-5 approach. Nat Rev Neurol. 2014;10(11):634–642. PubMed CrossRef
  17. Latimer KM, Gunther A, Kopec M. Fatigue in adults: evaluation and management. Am Fam Physician. 2023;108(1):58–69. PubMed
  18. Sanger TD, Chen D, Fehlings DL, et al. Definition and classification of hyperkinetic movements in childhood. Mov Disord Off J Mov Disord Soc. 2010;25(11):1538–1549. PubMed CrossRef
  19. Jellinger KA. Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update. II. Hyperkinetic disorders. J Neural Transm. 2019;126(8):997–1027. PubMed CrossRef
  20. Duden GS, Gersdorf S, Stengler K. Global impact of the COVID-19 pandemic on mental health services: a systematic review. J Psychiatr Res. 2022;154:354–377. PubMed CrossRef
  21. Nochaiwong S, Ruengorn C, Thavorn K, et al. Global prevalence of mental health issues among the general population during the Coronavirus disease-2019 pandemic: a systematic review and meta-analysis. Sci Rep. 2021;11(1):10173. PubMed CrossRef
  22. Sonmez A, Warner C, Olsen S, et al. Covid effects on clinical outcomes of TMS treatment: a naturalistic study. Brain Stimul. 2021;14(6):1678. CrossRef
  23. Dörks M, Jobski K, Hoffmann F, et al. Global COVID-19 pandemic and reporting behavior—an analysis of the Food and Drug Administration Adverse Events Reporting System. Pharmacoepidemiol Drug Saf. 2021;30(6):707–715. PubMed
  24. Scheper A, Rosenfeld C, Dubljević V. The public impact of academic and print media portrayals of TMS: shining a spotlight on discrepancies in the literature. BMC Med Ethics. 2022;23(1):25. PubMed CrossRef
  25. Kazemi R, Rostami R, Rezaei M, et al. Comorbid anxiety in depression and rTMS treatment response: a retrospective study. J Affect Disord. 2025;376:36–46. PubMed CrossRef
  26. Maizey L, Allen CPG, Dervinis M, et al. Comparative incidence rates of mild adverse effects to transcranial magnetic stimulation. Clin Neurophysiol Off J Int Fed Clin Neurophysiol. 2013;124(3):536–544. PubMed CrossRef
  27. Harris A, Reece J. Transcranial magnetic stimulation as a treatment for posttraumatic stress disorder: a meta-analysis. J Affect Disord. 2021;289:55–65. PubMed CrossRef
  28. McClintock SM, Kallioniemi E, Martin DM, et al. A critical review and synthesis of clinical and neurocognitive effects of noninvasive neuromodulation antidepressant therapies. Focus J Life Long Learn Psychiatry. 2019;17(1):18–29. PubMed CrossRef
  29. Iimori T, Nakajima S, Miyazaki T, et al. Effectiveness of the prefrontal repetitive transcranial magnetic stimulation on cognitive profiles in depression, schizophrenia, and Alzheimer’s disease: a systematic review. Prog Neuropsychopharmacol Biol Psychiatry. 2019;88:31–40. PubMed CrossRef
  30. Zis P, Shafique F, Hadjivassiliou M, et al. Safety, tolerability, and nocebo phenomena during transcranial magnetic stimulation: a systematic review and meta-analysis of placebo-controlled clinical trials. Neuromodulation J Int Neuromodulation Soc. 2020;23(3):291–300. PubMed CrossRef
  31. Rock PL, Roiser JP, Riedel WJ, et al. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med. 2014;44(10):2029–2040. PubMed CrossRef
  32. Taylor JJ, Newberger NG, Stern AP, et al. Seizure risk with repetitive TMS: survey results from over a half-million treatment sessions. Brain Stimul. 2021;14(4):965–973. PubMed CrossRef
  33. Lisanby SH. Transcranial magnetic stimulation safety and risk—National Institute of Mental Health (NIMH). 2020. Accessed May 20, 2025. https://www.nimh.nih.gov/news/media/2020/sarah-h-lisanby-transcranial-magnetic-stimulation-safety-and-risk
  34. Ramos MRF, Goerigk S, Aparecida Da Silva V, et al. Accelerated theta-burst stimulation for treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2025;82(5):442–450. PubMed CrossRef
  35. Abdelnaim MA, Langguth B, Deppe M, et al. Anti-suicidal efficacy of repetitive transcranial magnetic stimulation in depressive patients: a retrospective analysis of a large sample. Front Psychiatry. 2020;10:929. PubMed CrossRef
  36. Ventura F, Frias P, Rodrigues da Silva D, et al. Efficacy, effectiveness, and safety of transcranial magnetic stimulation for bipolar depression: a systematic review and meta-analysis. Biol Psychiatry Glob Open Sci. 2026;6(1):100618. PubMed CrossRef
  37. Xia G, Gajwani P, Muzina DJ, et al. Treatment-emergent mania in unipolar and bipolar depression: focus on repetitive transcranial magnetic stimulation. Int J Neuropsychopharmacol. 2008;11(1):119–130. PubMed CrossRef
  38. Miuli A, Sepede G, Stigliano G, et al. Hypomanic/manic switch after transcranial magnetic stimulation in mood disorders: a systematic review and meta-analysis. World J Psychiatry. 2021;11(8):477–490. PubMed CrossRef
  39. Pascual-Leone A, Cohen LG, Shotland LI, et al. No evidence of hearing loss in humans due to transcranial magnetic stimulation. Neurology. 1992;42(3):647–647. PubMed CrossRef
  40. Tringali S, Perrot X, Collet L, et al. Repetitive transcranial magnetic stimulation: hearing safety considerations. Brain Stimul. 2012;5(3):354–363. PubMed CrossRef
  41. Koponen LM, Goetz SM, Peterchev AV. Double-containment coil with enhanced winding mounting for transcranial magnetic stimulation with reduced acoustic noise. IEEE Trans Biomed Eng. 2021;68(7):2233–2240. PubMed CrossRef
  42. Overvliet GM, Jansen RAC, van Balkom AJLM, et al. Adverse events of repetitive transcranial magnetic stimulation in older adults with depression, a systematic review of the literature. Int J Geriatr Psychiatry. 2021;36(3):383–392. PubMed CrossRef
  43. Kramer DB, Xu S, Kesselheim AS. Regulation of medical devices in the United States and European Union. N Engl J Med. 2012;366:848–855. PubMed CrossRef
  44. Tubbs A, Vazquez EA. Engineering and technological advancements in repetitive transcranial magnetic stimulation (rTMS): a five-year review. Brain Sci. 2024;14(11):1092. PubMed CrossRef
  45. Everhart AO, Karaca-Mandic P, Redberg RF, et al. Late adverse event reporting from medical device manufacturers to the US Food and Drug Administration: cross sectional study. The BMJ. 2025;388:e081518. PubMed CrossRef
  46. Leocani L, Dalla Costa G, Coppi E, et al. Repetitive transcranial magnetic stimulation with H-coil in Alzheimer’s disease: a double-blind, placebo-controlled pilot Study. Front Neurol. 2021;11:614351. PubMed CrossRef
  47. Ueno S, Sekino M. Figure-eight coils for magnetic stimulation: from focal stimulation to deep stimulation. Front Hum Neurosci. 2021;15:805971. PubMed CrossRef
  48. Zeng Z, Koponen LM, Hamdan R, et al. Modular multilevel TMS device with wide output range and ultrabrief pulse capability for sound reduction. J Neural Eng. 2022;19(2). doi:10.1088/1741-2552/ac572c. PubMed CrossRef
  49. Gattinger N, Mossnang G, Gleich B. flexTMS—A novel repetitive transcranial magnetic stimulation device with freely programmable stimulus currents. IEEE Trans Biomed Eng. 2012;59(7):1962–1970. PubMed CrossRef
  50. Cole EJ, Stimpson KH, Bentzley BS, et al. Stanford Accelerated Intelligent Neuromodulation Therapy for treatment-resistant depression. Am J Psychiatry. 2020;177(8):716–726. PubMed CrossRef
  51. Canini F, Claverie D, Weill F, et al. Auricular neuromodulation may act through interoception modulation. Brain Res. 2025;1863:149736. PubMed CrossRef
  52. Lai M, Xiao J, Zhan J, et al. Paired associative electroacupuncture and transcranial magnetic stimulation induced plasticity in human primary motor cortex. Clin Neurophysiol Off J Int Fed Clin Neurophysiol. 2025;178:2110969. PubMed CrossRef
  53. Qin Y, Liu X, Zhang Y, et al. Effects of transcranial combined with peripheral repetitive magnetic stimulation on limb spasticity and resting-state brain activity in stroke patients. Front Hum Neurosci. 2023;17:992424. PubMed CrossRef

About the Authors

Buy PDF for $40

Please sign in or purchase this PDF for $40.

Figure. Journal cover highlights articles on bipolar II depression therapy, schizophrenia treatment, and adult ADHD symptoms.

Vol 86 • 2025 • Number 4

Read the Current Issue

Original Research

Effects of Interpersonal and Social Rhythm Therapy on Suicidal Ideation in Adults with Bipolar II Depression

Academic Highlights

Real-World Implementation of Xanomeline-Trospium in Schizophrenia: A Consensus Panel Report

Academic Highlights

Psychosocial Interventions and Functional Recovery in Schizophrenia

Original Research

Symptom Network Analysis of ADHD and Emotional Symptoms in Adults

Original Research

Emory Treatment Resistance Interview for PTSD—Short Version

Original Research

Brexpiprazole for the Treatment of Co-Occurring Schizophrenia and Substance Use Disorder
View current Issue

Consensus Report on XT Use in Practice

Read the full report
Figure: Graphic promoting Consensus Report on Xanomeline-Trospium; colorful net design shown with JCP logo in lower left.

Subscribe to read
more articles

Subscribe